Ginkgo Bioworks Raises $100M in Series C Funding Round | GenomeWeb

NEW YORK (GenomeWeb) – Organism design company Ginkgo Bioworks announced today that it has raised $100 million in a Series C funding round.

The firm said it plans to use the funds to grow into new markets such as commodity chemicals, industrial enzymes, and human health markets. It also plans to build a next-generation automated foundry called Bioworks2 where Ginkgo's organism engineers can develop new designs at a larger scale.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.